TECH vs RVTY

For growth investors, Bio-Techne Corporation (TECH) is the stronger pick with 5.

2% revenue growth year-over-year, versus 3. 7% for Revvity, Inc. (RVTY). Revvity, Inc. (RVTY) offers the better valuation at 47. 5x trailing P/E (18. 3x forward), making it the more compelling value choice. Analysts rate Bio-Techne Corporation (TECH) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Revvity, Inc.

(RVTY) is the cheapest at 47. 5x versus Bio-Techne Corporation at 110. 7x. On forward P/E, Revvity, Inc. is actually cheaper at 18. 3x.

Over the past 5 years, Revvity, Inc.

(RVTY) delivered a total return of -28. 9%, compared to -50. 3% for Bio-Techne Corporation (TECH). Over 10 years, the gap is even starker: TECH returned +112. 5% versus RVTY's +88. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Techne Corporation (TECH) is the lower-risk stock at 1.

41β versus Revvity, Inc. 's 1. 57β — meaning RVTY is approximately 11% more volatile than TECH relative to the S&P 500. On balance sheet safety, Bio-Techne Corporation (TECH) carries a lower debt/equity ratio of 23% versus 48% for Revvity, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bio-Techne Corporation (TECH) is pulling ahead at 5.

2% versus 3. 7% for Revvity, Inc. (RVTY). On earnings-per-share growth, the picture is similar: Revvity, Inc. grew EPS -13. 7% year-over-year, compared to -56. 2% for Bio-Techne Corporation. Over a 3-year CAGR, TECH leads at 3. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Revvity, Inc.

(RVTY) is the more profitable company, earning 8. 5% net margin versus 6. 0% for Bio-Techne Corporation — meaning it keeps 8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVTY leads at 12. 5% versus 8. 4% for TECH. At the gross margin level — before operating expenses — TECH leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Revvity, Inc.

(RVTY) trades at 18. 3x forward P/E versus 25. 7x for Bio-Techne Corporation — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TECH: 36. 2% to $69. 33.

All stocks in this comparison pay dividends.

Bio-Techne Corporation (TECH) offers the highest yield at 0. 6%, versus 0. 3% for Revvity, Inc. (RVTY).

For long-horizon retirement investors, Bio-Techne Corporation (TECH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

6% yield, +112. 5% 10Y return). Revvity, Inc. (RVTY) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TECH: +112. 5%, RVTY: +88. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

TECH pays a dividend while RVTY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.